595P Durable efficacy of zenocutuzumab, a HER2 x HER3 bispecific antibody, in advanced NRG1 fusion-positive (NRG1+) non-small cell lung cancer (NSCLC)

D-W. Kim, K. Goto, A. Schram, A. Hollebecque, S.Y. Rha, K. Nishino, M. Duruisseaux, K. Umemoto, J.O. Park, N. Leighl,T. Macarulla Mercade, S.V. Liu, M.N. Al-Hallak, J. Cleary, C. Neuzillet, Y. Goto, A.K. Joe, S. Adeyemi, S. Jauhari, A. Drilon

Annals of Oncology（2023）

引用 0|浏览4